Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program
\n<\/p>\n
By signing a Memorandum of Understanding with leading Russian pharmaceutical holding companies National Immunobiological Company (Nacimbio) and Pharmstandard, Kedrion Biopharma further strengthens its presence in Russia.<\/p>\n
Kedrion Biopharma and Nacimbio, part of the State-owned Rostec group, whose mission is to reduce Russian dependence from the importation of life-saving human plasma derived therapies, are joined by new partner Pharmastandard, a leading Russian company specializing in the development and manufacturing of pharmaceutical products.<\/p>\n
This Italian-Russian partnership aims to implement a joint program that will lead to manufacturing plasma-derived products in the Russian Federation; specifically, it aims to finalize the construction of production plant in Kirov, Russia.<\/p>\n
The parties are committed to establishing – by January 2017 – a joint venture, shares in which will be owned by Nacimbio (37.5%), Pharmastandard (37.5%) and Kedrion (25%). The joint venture will determine the industrial plan for, and complete the construction of, the Kirov-based plant. In the new organization, Kedrion will uphold its role as principal technological partner, whereas Pharmastandard steps in to provide financial backing. <\/p>\n
“The Memorandum signed today is the basis for the successful implementation of a project that is a key priority for Russian healthcare” – commented Sergey Chemezov, CEO of the State Corporation Rostec, at the signing of the document. <\/p>\n
“Nacimbio was created for implementing multilevel projects such as this – stated Mariam Khubieva, CEO of Nacimbio; we will make every effort, and engage the country’s best resources, to ensure the production facility begins its operations within the set deadline”.<\/p>\n
Paolo Marcucci, CEO of Kedrion Biopharma, stressed the importance of the Memorandum for the company: “We strongly believe in this joint venture with Nacimbio and Pharmstandard, two leading Russian pharmaceutical players. The entire project, and the completion of the production facility in Russia, represent a further milestone in the long-term international growth strategy pursued by our company”.<\/p>\n
“For Pharmstandard, entering this joint venture means supporting the common effort towards making Russia independent of plasma product imports”, stated the Operations Director of Pharmstandard, Vladimir Chupikov.<\/p>\n","protected":false},"featured_media":0,"template":"","categories_news":[45],"class_list":["post-3864","news","type-news","status-publish","hentry","categories_news-corporate-en"],"acf":[],"yoast_head":"\n